Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) major shareholder Ra Capital Management, Llc unloaded 4,235,000 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $9.53, for a total transaction of $40,359,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 9.79 on Thursday. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $10.18. The stock’s 50-day moving average is $7.49 and its 200-day moving average is $4.73. The company’s market cap is $957.3 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings data on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.69 earnings per share for the current fiscal year.

A number of research firms have recently commented on ACHN. Analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday. They now have a $17.00 price target on the stock, up previously from $6.00. Separately, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. Finally, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. They set an “outperform” rating and a $12.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $8.90.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.